Ultromics is a technology company.
Ultromics has raised $101.0M across 3 funding rounds.
Ultromics has raised $101.0M in total across 3 funding rounds.
Ultromics has raised $101.0M in total across 3 funding rounds.
Ultromics's investors include HealthQuest Capital, Sandbox Industries, 24Haymarket.
Ultromics is an AI-powered medical technology company that develops the EchoGo® platform to enhance echocardiogram analysis for early detection of complex heart diseases, particularly heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis.[1][2][4] It serves hospitals, echo labs, and health systems by integrating seamlessly into existing workflows via cloud-based DICOM processing, delivering automated reports in under 20 minutes to reduce unnecessary tests, streamline diagnostics, and enable earlier treatment—addressing the undiagnosed cases among 64 million global heart failure patients.[1][2][4] With FDA clearances, Medicare reimbursement, and recent $55M Series C funding, Ultromics shows strong growth, expanding U.S. adoption and its pipeline for additional cardiac conditions.[1]
Ultromics originated from the University of Oxford, founded in 2017 as a spin-out after Ross Upton, working with Professor Paul Leeson, developed the initial EchoGo algorithm to overcome limitations in traditional echocardiogram analysis.[1][2] The idea emerged from addressing diagnostic challenges in heart failure phenotypes like HFpEF, leveraging deep learning trained on Mayo Clinic's outcome database for single-view disease detection.[2] Early traction built through NHS partnerships and clinical studies, leading to rapid milestones: over 20 published studies, three FDA clearances (including Breakthrough Device for EchoGo® Amyloidosis in 2024 and EchoGo® Score in 2025), CE marks, and Medicare codes by 2025.[1][2]
Ultromics rides the wave of AI in medical imaging, specifically cardiology, where echocardiography limitations hinder early heart failure detection amid a global epidemic affecting 64 million.[2][4] Timing aligns with health systems combating rising cases, post-2024/2025 regulatory wins enabling scaled U.S. adoption as AI diagnostics become workflow defaults.[1] Favorable market forces include Medicare reimbursement, pharma/academic collaborations (e.g., Mayo, J&J, MedStar) for trials/biomarkers, and AI's role in reducing variability—proven in COVID mortality prediction.[5][6] It influences the ecosystem by setting standards for reimbursable AI, partnering with leaders to accelerate discoveries, and easing provider burden in overburdened systems.[1][5]
Ultromics is poised for U.S. dominance with its $55M Series C fueling hospital expansions, pipeline growth (new conditions/channels), and deeper health system ties amid AI cardiology demand.[1] Trends like outcome-linked reimbursement and collaborative AI will propel it, potentially evolving from diagnostic leader to ecosystem enabler for trials and therapies. As heart failure crises intensify, Ultromics' Oxford-honed precision could redefine early intervention, tying back to its mission of turning elusive diagnoses into scalable, life-saving defaults.[1][2]
Ultromics has raised $101.0M across 3 funding rounds. Most recently, it raised $55.0M Series C in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $55.0M Series C | HealthQuest Capital, Sandbox Industries | |
| Aug 1, 2021 | $33.0M Series B | HealthQuest Capital, Sandbox Industries | |
| May 1, 2018 | $13.0M Series A | 24Haymarket |